Vice President, Process Sciences

Director, Contracts Attorney

Vice President, Clinical Development

Scientist I, T Cell Stemness

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

Lyell Immunopharma is using the latest insights in immunology to reprogram T cells to cure cancer. CAR T cells have had most success so far in treating patients with B cell lymphomas. However, around 90% of all cancers are solid tumors where only limited success with cell therapies has been seen. Lyell is using their proprietary epigenetic and genetic reprogramming technologies to develop cell therapies to address these tumors for reliable and curative responses. Lyell’s approach involves identifying the “active ingredient” of adoptive cell therapies to either overcome loss of T cell function or to create T cell populations with durable stemness to infiltrate tumors. Lyell’s lead product, LYL797 is in Phase 1 clinical trials for non-small cell lung cancer, with other products in the pipeline.

<p>Lyell Immunopharma is using the latest insights in immunology to reprogram T cells to cure cancer. CAR T cells have had most success so far in treating patients with B cell lymphomas. However, around 90% of all cancers are solid tumors where only limited success with cell therapies has been seen. Lyell is using their proprietary epigenetic and genetic reprogramming technologies to develop cell therapies to address these tumors for reliable and curative responses. Lyell’s approach involves identifying the “active ingredient” of adoptive cell therapies to either overcome loss of T cell function or to create T cell populations with durable stemness to infiltrate tumors. Lyell’s lead product, LYL797 is in Phase 1 clinical trials for non-small cell lung cancer, with other products in the pipeline.</p>


Find a biotech startup job.